A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

被引:66
|
作者
He, Qiliang [1 ,2 ]
Colon-Motas, Kay M. [3 ]
Pybus, Alyssa F. [1 ,2 ,4 ,5 ]
Piendel, Lydia [3 ]
Seppa, Jonna K. [3 ]
Walker, Margaret L. [3 ,6 ]
Manzanares, Cecelia M. [3 ,6 ]
Qiu, Deqiang [1 ,2 ,6 ,7 ]
Miocinovic, Svjetlana [1 ,2 ,3 ,6 ]
Wood, Levi B. [1 ,2 ,4 ,5 ]
Levey, Allan I. [3 ,6 ]
Lah, James J. [3 ,6 ]
Singer, Annabelle C. [1 ,2 ]
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr,UAWSuite 3105, Atlanta, GA 30332 USA
[2] Emory Univ, Atlanta, GA 30332 USA
[3] Emory Univ, Emory Brain Hlth Ctr, Dept Neurol, Atlanta, GA USA
[4] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA
[5] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA USA
[6] Emory Univ, Goizueta Alzheimer Dis Res Ctr, Atlanta, GA USA
[7] Emory Univ, Dept Radiol & Imaging Sci, Sch Med, Atlanta, GA USA
关键词
amyloid beta; cytokines; default mode network; electrophysiology; feasibility trial; gamma stimulation; neural stimulation; prodromal Alzheimer's disease; sensory stimulation; PHASE-I TRIAL; STEM-CELLS; BRAIN; STIMULATION; MICROGLIA;
D O I
10.1002/trc2.12178
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction We and collaborators discovered that flickering lights and sound at gamma frequency (40 Hz) reduce Alzheimer's disease (AD) pathology and alter immune cells and signaling in mice. To determine the feasibility of this intervention in humans we tested the safety, tolerability, and daily adherence to extended audiovisual gamma flicker stimulation. Methods Ten patients with mild cognitive impairment due to underlying AD received 1-hour daily gamma flicker using audiovisual stimulation for 4 or 8 weeks at home with a delayed start design. Results Gamma flicker was safe, tolerable, and adherable. Participants' neural activity entrained to stimulation. Magnetic resonance imaging and cerebral spinal fluid proteomics show preliminary evidence that prolonged flicker affects neural networks and immune factors in the nervous system. Discussion These findings show that prolonged gamma sensory flicker is safe, tolerable, and feasible with preliminary indications of immune and network effects, supporting further study of gamma stimulation in AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
    Enrica Cavedo
    Michel J. Grothe
    Olivier Colliot
    Simone Lista
    Marie Chupin
    Didier Dormont
    Marion Houot
    Stephane Lehéricy
    Stefan Teipel
    Bruno Dubois
    Harald Hampel
    Scientific Reports, 7
  • [42] An update on the use of gamma (multi)sensory stimulation for Alzheimer's disease treatment
    Manippa, Valerio
    Palmisano, Annalisa
    Filardi, Marco
    Vilella, Davide
    Nitsche, Michael A.
    Rivolta, Davide
    Logroscino, Giancarlo
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [43] Erratum to: Alzheimer’s Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease
    Suzanne B. Hendrix
    H. Soininen
    A. M. J. van Hees
    N. Ellison
    P. J. Visser
    A. Solomon
    A. Attali
    K. Blennow
    M. Kivipelto
    T. Hartmann
    The Journal of Prevention of Alzheimer's Disease, 2023, 10 : 151 - 151
  • [44] Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer's Disease in Spain
    Mar, Javier
    Ibarrondo, Oliver
    Larranaga, Igor
    Mar-Barrutia, Lorea
    Soto-Gordoa, Myriam
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [45] Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
    Laure Saint-Aubert
    Emmanuel J Barbeau
    Patrice Péran
    Federico Nemmi
    Celine Vervueren
    Helene Mirabel
    Pierre Payoux
    Anne Hitzel
    Fabrice Bonneville
    Raluca Gramada
    Mathieu Tafani
    Christian Vincent
    Michele Puel
    Sophie Dechaumont
    Francois Chollet
    Jeremie Pariente
    EJNMMI Research, 3
  • [46] Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
    Javier Mar
    Oliver Ibarrondo
    Igor Larrañaga
    Lorea Mar-Barrutia
    Myriam Soto-Gordoa
    Alzheimer's Research & Therapy, 14
  • [47] Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients
    Saint-Aubert, Laure
    Barbeau, Emmanuel J.
    Peran, Patrice
    Nemmi, Federico
    Vervueren, Celine
    Mirabel, Helene
    Payoux, Pierre
    Hitzel, Anne
    Bonneville, Fabrice
    Gramada, Raluca
    Tafani, Mathieu
    Vincent, Christian
    Puel, Michele
    Dechaumont, Sophie
    Chollet, Francois
    Pariente, Jeremie
    EJNMMI RESEARCH, 2013, 3 : 1 - 22
  • [48] Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage
    Drago, Valeria
    Babiloni, Claudio
    Bartres-Faz, David
    Caroli, Anna
    Bosch, Beatriz
    Hensch, Tilman
    Didic, Mira
    Klafki, Hans-Wolfgang
    Pievani, Michela
    Jovicich, Jorge
    Venturi, Luca
    Spitzer, Philipp
    Vecchio, Fabrizio
    Schoenknecht, Peter
    Wiltfang, Jans
    Redolfi, Alberto
    Forloni, Gianluigi
    Blin, Olivier
    Irving, Elaine
    Davis, Ceri
    Hardemark, Hans-goran
    Frisoni, Giovanni B.
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 26 : 159 - 199
  • [49] Clinical trial of donepezil on patients with Alzheimer's disease
    Zhang, X. Q.
    Dong, H. Q.
    Min, B. Q.
    JOURNAL OF ALZHEIMERS DISEASE, 2002, 4 (01) : 64 - 64
  • [50] Shift in the balance of TRKA and ProNGF in prodromal Alzheimer's disease
    Mufson, Elliott J.
    Counts, Scott E.
    Peng, S.
    Fahnestock, Margaret
    ADVANCES IN ALZHEIMER'S AND PARKINSON'S DISEASE: INSIGHTS, PROGRESS, AND PERSPECTIVES, 2008, 57 : 285 - +